Periodontal regeneration by leukocyte and platelet‐rich fibrin with autogenous bone graft versus enamel matrix derivative with autogenous bone graft in the treatment of periodontal intrabony defects: A randomized non‐inferiority trial. Issue 12 (17th June 2020)

• Record Type: Journal Article
• Authors: Paolantonio, Michele; Di Tullio, Marcella; Giraudi, Marta; Romano, Luigi; Secondi, Lorenzo; Paolantonio, Giulia; Graziani, Filippo; Pilloni, Andrea; De Ninis, Paolo; Femminella, Beatrice
• Is Part Of: Journal of periodontology. Volume 91:Issue 12(2020)
• Page Start: 1595
• Page End: 1608
• Publication Date: 2020-06-17
• Subjects: clinical trials -- dental enamel proteins -- grafts -- platelet‐rich fibrin -- regeneration -- wound healing; Periodontics -- Periodicals; 617.632
• DOI: 10.1002/JPER.19-0533
• Languages: English
• ISSNs: 0022-3492

Abstract

Abstract: Background: Aim of the present study was to ascertain if a combination of leukocyte and platelet‐rich fibrin (L‐PRF) + autogenous bone graft (ABG) may be a clinically "non‐inferior" treatment modality as compared with the association of enamel matrix derivative (EMD) with ABG in the management of intrabony defects (IBDs). Methods: A total of forty‐four patients, exhibiting at least one unfavorable intraosseous defect, were treated by L‐PRF associated with ABG (22 patients; test group) or EMD+ABG (control group) in each defect. At baseline and 12 months, a complete clinical and radiographic examination was done. Pre‐ and post‐therapy clinical (probing pocket depth [PPD], clinical attachment level [CAL], gingival recession [GR]) and radiographic (defect Bone level [(DBL)] parameters for the different treatments were compared. To guarantee the test treatment's efficacy 1mm was chosen as non‐inferiority margin; for clinical relevance, a second non‐inferiority margin = 0.5 mm was set. Results: Clinical and radiographic parameters significantly improved 12 months after surgery in both test and control sites, without inter‐groups differences for each measurement. The control group – test group differences for the parameters CAL gain −0.248 mm (−0.618 to 0.122), PPD Reduction −0.397 mm (−0.810 to 0.015), GR Change 0.059 mm (−0.300 to 0.418), DBL Gain −0.250 mm (−0.746 to 0.246) were all within the non‐inferiority margin of 0.5 mm. Conclusion: Our results suggest that the L‐PRF+ABG combined treatment of non‐contained IBDs produces non‐inferior results in terms of CAL gain, PPD reduction, GR increase and DBL gain in comparison with the EMD+ABG combination.